# README — Chunked Source Files for PDAC In Silico Triplicate Trial Paper

## Purpose of this README

This README documents 10 chunked Markdown files (`chunk_01_…md` through `chunk_10_…md`) derived from the source LaTeX project `main.tex` (3,624 lines) and BibTeX file `references.bib` (548 lines, 151 entries) for the paper:

> **Kawchak, K.** *ChatGPT 100,000 Patient 24-Month In Silico Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate.* Zenodo. 2025; 10.5281/zenodo.16415815.

The chunked files are intended as a reference corpus for **Claude Code Opus 4.7 (1M context) Max** when authoring a new physical AI oncology trial paper. The chunks preserve the original LaTeX content **word-for-word**, with no abbreviations, summarizations, or extra section headings introduced. The `.md` extension is for organizational convenience; the bodies remain raw LaTeX (including `\section`, `\subsection`, `\caption`, `\cite`, tabular environments, and so on).

Chunks 1–8 cover the full paper body of `main.tex` (Title, Abstract, Introduction, Methods, Parts I–V, Discussion, Limitations and Future Work, Conclusions, Data availability listing, all supplementary Prompt tables, Acknowledgments, Ethical disclosures, Rights and permissions, About this study). Chunks 9–10 contain the BibTeX bibliography. Concatenating chunks 1–8 reproduces `main.tex` lines 1–3621 exactly (lines 3622–3624 are trailing blank lines after `\end{document}` and are not included). Concatenating chunks 9–10 reproduces `references.bib` exactly (548 lines).

The `.sty` style file (`PRIMEarxiv.sty`) and image assets (figures under `images/` referenced via `\includegraphics`) are **not** included per the user's instructions. Image references remain visible in the LaTeX as `\includegraphics{images/...}` calls inside `\begin{figure}` blocks so that Claude Code can see exactly what figures are placed where and reproduce a similar visual layout for the new paper if desired.

---

## Paper at a Glance

**Author:** Kevin Kawchak (Chief Executive Officer, ChemicalQDevice, San Diego, CA). Date: July 24, 2025.

**Inquiry:** Whether ChatGPT can simulate three reproducible 100,000-patient pancreatic ductal adenocarcinoma (PDAC) Phase III clinical trial reports, internally and externally validated, cross-verified by other AI models, and compared clinically and financially to other trials.

**Design:** 5-arm Phase III in silico trial built around the **Daraxonrasib + Mitazalimab + liposomal Irinotecan** combination, with baseline characteristics and patient archetypes drawn from a prior Kawchak study (Proposal A, doi.org/10.5281/zenodo.15735068).

| Arm | Regimen |
| --- | ------- |
| A   | Triplet: Daraxonrasib + Mitazalimab + liposomal Irinotecan (D+M+I) |
| B   | Doublet: Mitazalimab + liposomal Irinotecan (M+I) |
| C   | Doublet: Daraxonrasib + liposomal Irinotecan (D+I) |
| D   | Doublet: Daraxonrasib + Mitazalimab (D+M) |
| E   | Control: nal-IRI + 5-FU |

**Six AI models orchestrating the pipeline** (these short codes recur in every chunk and are essential to understanding the cross-verification logic):

| Code | Model | Role |
| ---- | ----- | ---- |
| **o3ph** | OpenAI ChatGPT o3-pro Deep research | Generated ICH E3-aligned trial reports, log files, internal and external validations, meta-analysis, financial assessment |
| **g25p** | Google Gemini 2.5 Pro (AI Studio) | Processed 24 generations into the Virtual Trials Overview (1M-token context capability) |
| **grk4** | xAI Grok 4 | Cross-verification |
| **grk3** | xAI Grok 3 Think | Cross-verification |
| **o3pr** | OpenAI ChatGPT o3-pro | Cross-verification |
| **ops4** | Anthropic Claude Opus 4 Extended | Cross-verification + Python visualization scripts for most figures |

Auxiliary models referenced: **o3ch** (ChatGPT o3), **4och** (ChatGPT 4o), **o3re** (ChatGPT o3 Research), **son4** (Claude Sonnet 4 Extended), **45dr** (ChatGPT 4.5 Deep research).

**Headline Results:**
- 100,000 patients per trial × 3 trials. Per-arm n = 20,000.
- Overall Survival (OS) ordering by arm: A > D > E (as expected from multiplicative hazard ratios).
- Grade ≥3 AE ordering: A > D > E (control safest, as expected).
- PFS ordering: A > D > E.
- OS external validation vs. Flatiron Health dataset: **Pass** (Pearson r ≈ 0.999).
- ECOG external validation: **Fail** (simulated patients ~14–19% healthier than real-world cohort).
- KRAS-mutant vs. KRAS_G12C labeling discrepancy: ~86% deviation between report (>90% KRAS-mutant) and log (~5% KRAS_G12C), consistent across all three trials.
- Cross-trial reproducibility score (ops4, five-AI consensus): **8.65/10**.
- Three exact (<0.01) inter-model agreements: grk4–g25p, grk4–o3pr, g25p–o3pr.
- Recommendation: **Arm D** (Daraxonrasib + Mitazalimab) preferred over Arm A — comparable efficacy with substantially lower toxicity and better clinical feasibility than FOLFIRINOX (PRODIGE 4).
- Financial: Triplicate cost **$36,330** vs. $120K (single virtual run), $600K (QSP), $20M (Phase II), $100M (Phase III). Cost reduction 99.9997% vs. Phase III per patient. Estimated $19.96M saved by avoiding Arm A in-person trial. 55,000% ROI. 1-month time-to-decision (vs. 4.5 months to 5 years for comparators).
- Real-world Phase III comparators referenced throughout: **MPACT** (Gemcitabine + nab-Paclitaxel, 2013), **NAPOLI-1** (nal-IRI + 5-FU/LV, 2016), **PRODIGE 4 / ACCORD11** (FOLFIRINOX, 2011).

**Prompt-driven workflow** — the simulation is reproducible because every step is dictated by a numbered Prompt:

| Prompt | Purpose | Located in |
| ------ | ------- | ---------- |
| P30 (I/II + II/II) | The master simulation engine: configuration, archetypes, hazard models, safety model, biomarker adjustments, event generation, CSV file output, ICH E3 report structure | Chunk 7 |
| P32 | Internal validation: head-to-head report-vs-log file correlation (6 tables) | Chunk 7 |
| P34 / P35 / P36 | External validation: simulated cohort vs. Flatiron Health metastatic pancreatic cancer abstract | Chunk 7 |
| P33 | Trial chart generation from log files | Chunk 7 |
| P37 (I/II + II/II) | Trial-vs-trial cross-verification across 5 AI models | Chunk 7 |
| P38 | Cross-model visualization (Python via ops4) | Chunk 7 |
| P39 | Cross-trial visualization (Python via ops4) | Chunk 7 |
| P40 (I/II + II/II) | Log-vs-report meta-verification across 5 AI models | Chunk 7 |
| P41 | Cross-model meta-verification visualizations | Chunk 8 |
| P42 | Cross-trial meta-verification visualizations | Chunk 8 |
| P43 | Virtual Trials Overview synthesis (g25p, 24 inputs) | Chunk 8 |
| P43b1 / P43b2 | Trial overview chart prompts | Chunk 8 |
| P44 (I/III, II/III, III/III) | Meta-analysis vs. real-world Phase III trials (o3ph, Deep research) | Chunk 8 |
| P44b | Meta-analysis charts | Chunk 8 |
| P45 (I/IV, II/IV, III/IV, IV/IV) | Financial assessment & value proposition (o3ph) | Chunk 8 |
| P45b | Financial charts | Chunk 8 |

**Supplementary file ID convention** (S## codes appear throughout chunks 2–8 as `\cite`-style references inside captions and as filenames):
- `S33` / `S37` / `S40` = Trial reports 1 / 2 / 3 (via Prompt 30)
- `S33.LOG.CSV` / `S37.LOG.CSV` / `S40.LOG.CSV` = patient log files for trials 1 / 2 / 3
- `S35` / `S38` / `S41` = internal validation outputs (P32)
- `S35b` / `S38b` / `S41b` = external validation outputs (P34/P35/P36)
- `S36` / `S39` / `S42` = trial-log chart outputs (P33)
- `S43–S47` = trial-vs-trial cross-verifications by grk4, grk3, ops4, g25p, o3pr (P37)
- `S48`, `S49` = cross-model / cross-trial visualizations (ops4, P38/P39)
- `S50–S54` = log-vs-report meta-verifications across 5 models (P40)
- `S55`, `S56` = meta-verification visualizations (ops4, P41/P42)
- `S57` = Virtual Trials Overview (g25p, P43); `S57b` = its charts (P43b)
- `S58` = Meta-analysis (o3ph, P44); `S58b` = its charts (P44b)
- `S59` = Financial assessment (o3ph, P45); `S59b` = its charts (P45b)

---

## File-by-File Detail

### chunk_01_title_abstract_introduction.md
**Source:** `main.tex` lines 1–214 (214 lines).
**Contents (in order):**
- LaTeX preamble: `\documentclass{article}`, package imports (`PRIMEarxiv`, `tikz`, `pgfplots`, `circuitikz`, `tcolorbox`, `pgf-pie`, etc.), TikZ style definitions for flowchart nodes (`startstop`, `process`, `decision`, `arrow`), page geometry, header, and table styling.
- **Title:** "ChatGPT 100,000 Patient 24-Month *In Silico* Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate" (with two commented-out alternate titles preserved verbatim).
- **Author block:** Kevin Kawchak with ORCID 0009-0007-5457-8667, Chief Executive Officer, ChemicalQDevice, San Diego, CA, July 24, 2025, kevink@chemicalqdevice.com.
- **Structured Abstract** with six labeled paragraphs: **Inquiry**, **Concept**, **Results**, **Outputs**, **Impacts**, **Outcome**. Defines the entire study premise, lists the six AI models, summarizes the per-arm hazard outcomes, the KRAS labeling issue, the Flatiron Health external validation passing for OS and failing for ECOG, the financial assessment ($36,330 vs. $20M Phase II vs. $100M Phase III), and the 99.9997% cost reduction.
- **Table of Contents:** `\tableofcontents` directive.
- **Main pipeline figure:** `\includegraphics{images/MainDiagramSimPDAC}` with caption "PDAC 100K Patient In Silico Clinical Trial Pipeline" (label `MainProcessTriplicate`).
- **Section: Introduction** with two subsections:
  - *LLMs Benefit In Silico Studies* — frames prior work by Kawchak (PDAC, glioblastoma, lung adenocarcinoma trials), meta-prompting on a 408,081-word dataset using g25p's 1M-token context, and best-of-10 scoring of five virtual clinical trial proposals (o3pr scored highest at 9.09).
  - *In Silico Studies, Local Trials* — literature review covering: Arcus Biosciences PRISM-1 study with Dr. Zev Wainberg quote on synthetic arms; Arcus ARC-8 with 37% reduction in death risk and 5.9-month median OS improvement vs. 122-patient Synthetic Control Arm®; Nature Cancer 2024 Molecular Twin AI platform (6,363 features) from Johns Hopkins and Cedars-Sinai; Asghar et al. 2024 digital twin paper predicting nab-paclitaxel+gemcitabine response (LOR -0.090, p < 0.001); Toshimoto et al. 2024 IO-QSP model; 2025 Phase III AVATAR Trial by Sarno et al. (19.3 vs. 8.7 mo OS in the matched-drug subgroup); Ko et al. April 2025 MORPHEUS hybrid control arm trial (HR 0.91, 95% CI 0.56–1.49); Pourmousa et al. April 2025 UNC/MIT screening of 496 combinations × 32 anticancer compounds yielding 307 validated synergistic combinations.

**Correlates with:** Sets up every downstream chunk. The patient archetypes (ARCH-01 through ARCH-07), drug combination rationale, AI model selection logic, and methodology framework introduced here are operationalized in Chunk 2 (Methods, AI Models list, Patient Triplicate Log File Analysis) and detailed in Chunk 7 (Prompt 30). The Asghar et al. and Toshimoto et al. citations recur in Chunk 5 as Comparator In-Silico Study 1 in the meta-analysis tables. The "$36,330 estimated cost", "$19.96M cost savings", "55,000% ROI", and "Arm D recommended over Arm A" claims are all elaborated in Chunks 5–6 and substantiated in Chunk 8 (Prompt 45 financial assessment). The six AI models named here drive the cross-verification logic in Chunks 4 (Part II) and 8 (Prompts P37, P40).

### chunk_02_methods_part1_patient_log_analysis.md
**Source:** `main.tex` lines 215–465 (251 lines).
**Contents (in order):**
- **Section: Methods**
  - *Subsection: In Silico Trials, Logs, Validations* — describes the TSVS score (8.15) for Daraxonrasib + Mitazalimab + liposomal Irinotecan, Weibull shape parameter, multiplicative hazard ratios, synergy factors, biomarker adjustments, event times for 100,000 single-row synthetic patient records across eleven clinical indicators. Defines the terminology: "triplicate" = three-trial study, "triplet" = Arm A, "doublet" = Arms B/C/D, control = Arm E. Lists Prompts: Prompt 32 (internal validation, refs S35, S38, S41); Prompts 34–36 (external validation against Flatiron Health, refs S35b, S38b, S41b); Prompt 30 (chart visualizations); five-model cross-verification via Prompt 37 yielding outputs S43–S47; meta-verifications via Prompt 40 yielding S50–S54; ops4 visualizations S48, S49, S55, S56; g25p virtual trials overview S57 from 24 input generations; ops4 chart visualizations S57b.
  - *Subsection: External Studies: Meta-Analysis, Economics* — covers Prompt 44 (9,574-word meta-analysis via o3ph Deep research, comparing the triplicate to MPACT, NAPOLI-1, PRODIGE 4 and two in-silico trials, output S58 with charts S58b). Prompt 45 financial assessment via o3ph (S59) with charts S59b. Lists all 11 AI models accessed (o3ph, g25p, grk4, grk3, o3pr, ops4, o3ch, 4och, o3re, son4, 45dr) with bullet-pointed descriptions including access method (ChatGPT pro chat, Google AI Studio playground, Grok SuperGrok, Claude professional plan) and specific settings — e.g., g25p configuration: Temp=1, Thinking mode=On, Thinking budget=32768, Output length=65536, Top P=0.95, all safety/grounding/structured-output settings OFF.
- **Section: Part I: PDAC Triplicate Trials**
  - **Table: Patient Triplicate Log File Analysis** (label `LogAnalysisTable`, caption "Seven Patient/Archetype Analyses, o3ph. Ref: S33, S37, S40") — three sub-tables (Trial 1, Trial 2, Trial 3) each showing 7 patients (IDs 000001, 023649, 046253, 050205, 057254, 069416, 100000) corresponding to archetypes ARCH-01 through ARCH-07, with 12 columns: patient_id, arm, archetype, age, stage_iv (1/0), ecog (0/1/2), kras_g12c (1/0), gbrca (1/0), ca19_9, time_to_progression_or_death (PFS), time_to_death (OS), time_to_first_G3_AE. Below each table, a 7-row narrative summary per patient (e.g., "Patient 000001 had stage IV disease (ECOG 0), KRAS G12C -, BRCA wild-type, CA19-9 4013.9 U/mL; OS 20.2 mo, PFS 16.1 mo.").
  - *Subsection: Patient Triplicate Log File Analysis* — explains how patients 000001 and 100000 were held constant (ARCH-01 and ARCH-07), patients for ARCH-02 through ARCH-06 were randomly selected by o3pr, Trials 2 and 3 reused the same patient IDs. Discusses uncensored exponential draws producing some apparently anomalous values (e.g., Trial 1 Patient 046253 time-to-first-G3-AE 23.85 mo > OS 1.86 mo) explained by Prompt 30 instruction to censor at 24 months only for the report-level KM analysis. Cumulative results (Table 6-1) gave mPFS ~4 mo vs. mOS ~8 mo for Arm A.
- **Figures 2–5 (referenced in this chunk's text but appearing as `\includegraphics` blocks):** Trial 1 Violin Plot of Treatment Arms (LogImage1, image `S36.VIS.01.P33-16`, text box "Arm Trials OS: A > D > C > B > E"); Trial 2 Grade ≥3 AE Incidence by Arm (LogImage2, image `S39.VIS.01.P33-12.png`, "Grade ≥3 AEs: E < D < C < B < A"); Trial 3 Kaplan-Meier PFS Curves by Arm (LogImage3, image `S42.VIS.01.P33-07`, "Trial Arms PFS: A > D > C > B > E"); Trial 3 OS by ECOG Status (LogImage4, image `S42.VIS.01.P33-17`, "Highest Survival for Arm A ECOG 0/1/2"). Each figure is followed by a tcolorbox annotation explaining the interpretation.
- Closing paragraph correlates each figure with the Prompt 30 hazard parameters (OS HR Daraxonrasib 0.85 vs. Mitazalimab 0.90, synergy 0.90 for triplet; monthly G3+ AE probability 0.12 for A vs. 0.06 for E; PFS HR Daraxonrasib 0.80 vs. Mitazalimab 0.95).

**Correlates with:** All S## references in captions point to supplementary files whose generating prompts are in Chunks 7–8. The drug hazard parameters cited here (0.85, 0.90, 0.80, 0.95, 0.90 synergy, 0.12/0.09/0.08/0.07/0.06 AE probabilities) are defined verbatim in Chunk 7's Prompt 30 (I/II). The seven patient log entries here can be cross-checked against the report values cross-referenced in Chunk 3's internal validation tables. The five-model cross-verification framework introduced in Methods is fully realized in Chunk 4 (Part II) and prompted in Chunk 7's Prompt 37.

### chunk_03_part1_internal_external_validations.md
**Source:** `main.tex` lines 466–779 (314 lines).
**Contents (in order):**
- *Subsection: Internal and External Validations* — narrative paragraph summarizing that report values vs. log values matched within ~0.4% across most baseline characteristics (age, stage, ECOG), except for **KRAS-mutant deviation of 85.8% / 86.1% / 86.2%** across the three trials, attributed to the report reporting "KRAS-mutant >90% in pancreatic cancer" while the log reports "KRAS_G12C <1–2% of KRAS-mutants". External OS validation against Flatiron Health passed all three trials; ECOG validation showed up to 19.1% absolute difference (simulated cohort healthier than real-world).
- **Large table: Trial Analysis & External Validations** (label `TriplicateAnalysisTable`, caption "High KRAS-mutant Deviation. Low ECOG 2. Ref: S33, S37, S40, S35, S38, S41, S35b, S38b, S41b") containing nine sub-tables:
  - **Trial 1 / 2 / 3 Table 5-1: Baseline Characteristics by Arm** (5 rows × 9 columns): Arm, Age (years, mean), Stage IV (%), ECOG 0 (%), ECOG 1 (%), ECOG 2 (%), KRAS-mutant (%), gBRCA-mutant (%), CA19-9 (U/mL, mean). Values per arm are ~66.2–66.4 years age, ~88% Stage IV, ~20%/74%/6% ECOG 0/1/2, ~91% KRAS-mutant, 5% gBRCA, ~5,800–5,880 U/mL CA19-9 — extraordinarily consistent across arms and trials.
  - **Trial 1 / 2 / 3 Table 2: Baseline Characteristics Correlations** (5 rows × 4 columns): Characteristic, Reported Value (Table 5-1), Calculated Value (from Log), Deviation (Absolute Difference). Mean age deviations ≤0.2 years; Stage IV deviations 0.1–0.2%; ECOG 1 deviations 0.1–0.5%; **KRAS-mutant deviations 85.8% / 86.1% / 86.2%**; gBRCA deviations 0.0–0.1%.
  - **Trial 1 / 2 / 3 Table T2: OS External Validation** (3 rows × 4 columns): Metric, Sim Value, Flatiron Value, Validation Note. Mean OS % at months 3–24 ~33.5–34.2% (sim) vs. 35.5% (Flatiron); SD of monthly absolute differences 1.2–1.4% vs. 0.0%; Pearson r 0.999 vs. 1.000. **All three pass.**
  - **Trial 1 / 2 / 3 Table T3: ECOG Validation** (3 rows × 4 columns): ECOG State, Sim %, Flatiron %, Absolute Difference %. ECOG 0: ~20% sim vs. 15% Flatiron (~5% diff); ECOG 1: ~74% sim vs. 60% Flatiron (~14% diff); ECOG 2: ~6% sim vs. 25% Flatiron (~19% diff). **All fail the ±5% threshold for ECOG 1 and 2.**
- **Multi-Model Cross-Verifications of Trials, ops4** — visual block (sets the stage for Part II in Chunk 4): Figures `CVImage1` (Inter-Model Consistencies for mPFS by Archetype, image `S48.VIS.01.P38-05.png`), `CVImage2` (Pairwise Model Agreement for Row Consistencies, image `S48.VIS.01.P38-03.png`, key insight "grk4=o3pr" r=1.0), `CVImage3` (Inter-Arm Consistency Scores by Category, image `S49.VIS.02.P39-04.png`, "8.95–9.45 Arm Averages Patterns"), `CVImage4` (Waterfall Chart of Metric Categories, image `S49.VIS.02.P39-10.png`, "8.65 Overall Trial Reproducibility Score").

**Correlates with:** The Table 5-1 baseline characteristics here are derived directly from Prompt 30's archetype prevalence table (Chunk 7). The Table 2 internal validation values are produced by Prompt 32 (Chunk 7). The Table T2/T3 external validation values are produced by Prompts 34/35/36 (Chunk 7) using the Flatiron Health metastatic pancreatic cancer abstract. The KRAS-mutant deviation issue (~86%) is the most-cited recurring finding in the paper and reappears in Chunk 4 (Virtual Trials Overview Table 04 R2 "Partial Concordance"), Chunk 6 (Discussion subsection "Multiple Verifications" and Conclusions), and the meta-verification consistency score of 10.0 in Chunk 4. The four CVImage figures introduced visually here are textually interpreted in Chunk 4's Part II subsection text.

### chunk_04_part2_cross_verifications_part3_overview.md
**Source:** `main.tex` lines 780–1031 (252 lines).
**Contents (in order):**
- **Multi-Model Cross-Verifications of Trials, ops4** — second figure block continuing from Chunk 3 (figures CVImage3 and CVImage4 already shown; CVImage1 and CVImage2 also appear).
- **Section: Part II: Cross-Verifications**
  - *Subsection: Patient Trial vs. Patient Trial* — text interpretation of CVImage1–4: control Arm E is most consistent (straightforward processing), waterfall reproducibility score is 8.65/10, g25p was most consistent across the 7 archetypes for mPFS row consistencies (4 scores ≥ 9.5), ops4 had lower but more consistent scores. Pairwise model agreement: **grk4 and o3pr at r=1.0**, several others above r=0.9.
- **Multi-Model Meta-Verifications: Logs vs. Trials, ops4** — figure block: MVImage1 (Inter-Model Agreement for Calculated Values, image `S55.VIS.01.P41-08.png`, "grk4-g25p, grk4-o3pr, g25p-o3pr" exact agreement <0.01), MVImage2 (Table Specific Deviations by Model, image `S55.VIS.01.P41-10.png`, "Table 3 (grk3) +1, Table 2-R1 (ops4) -0.9"), MVImage3 (Measurement Reliability Profiles across Arms, radar plot, image `S56.VIS.02.P42-04.png`), MVImage4 (Trial Value Distributions, ridge plot, image `S56.VIS.02.P42-10.png`, "10/10 Scores for Baseline KRAS/Cohorts", "8.8–10 Overall Range").
  - *Subsection: Log vs. Report Table vs. Trial* — text interprets the MVImage figures: radar plot shows close consistencies across dimensions for all five arms; ridge plot shows highest score (10) and narrowest distribution for Baseline KRAS; ops4 found three exact agreements (<0.01) among AI models; largest deviations were Table 3 by grk3 (+1) and Table 2-R1 by ops4 (-0.9).
- **Large table: Virtual Trials Overview** (label `VTOverviewTables`, caption "Overview Served as Input for Meta-Analysis, g25p. Ref: S57") containing four sub-tables produced by g25p synthesizing 24 prior generations:
  - **Table 01: 3 Virtual Trials Study Information** (row 1 only shown in chunk - "C1: Drug Combination(s)…") — high-level descriptor table.
  - **Table 02: 3 Virtual Trials - Technical Specifications** (row R1 = Details, 6 columns C1–C6): Drug Combination(s) — "Core Triplet: Daraxonrasib (KRAS G12C inhibitor) + Mitazalimab (immunotherapy) + liposomal Irinotecan", doublets and chemotherapy control. Patient Data Granularity — 7 archetypes, ECOG 0/1/2, KRAS_G12C, gBRCA, CA 19-9. Modeling Architecture — exponential survival, Weibull k=1.0, baseline mPFS 3.1 mo and mOS 6.1 mo, synergy factor 0.90. Project Timeline — July-August 2025 report date, random seed 20250624. Primary Endpoints — co-primary OS and PFS; secondary: 12-month OS rates and Grade ≥3 AE incidence. Key AI Models — grk4, grk3, ops4, g25p, o3pr.
  - **Table 04: Reproducibility and Validation Findings** (4 rows × 2 columns):
    - R1 OS: High external concordance (Pearson r 0.999, ±5% threshold met); high internal reproducibility (Arm A mean OS 8.73 mo, range only 0.1 mo across trials, consistency scores 8.98 and 9.08 across 5 AI models).
    - R2 Baseline Characteristics: **Partial Concordance** (ECOG failed by 5%, 14%, 19% differences for ECOG 0, 1, 2); **Exceptional Reproducibility** (consistency scores ≥ 9.8 across all baseline metrics; the KRAS-mutant deviation itself scored 10.0 for consistency — i.e., the discrepancy was identical across trials).
    - R3 Cross-Model: "Strong Inter-Model Agreement"; "tight cluster" for grk4, g25p, o3pr; grk3 and ops4 as minor outliers (S55). Programmatic visualization scripts (e.g., `01_heatmap_consistency_scores.py` from S48).
    - R4 Overall Reproducibility: "Highly Robust", percentage-based metrics (AE rates) had higher consistency than time-to-event metrics (median OS).
- **Section: Part III: Virtual Trials Overview**
  - *Subsection: Reproducibility: Validations, Cross-Model* — single paragraph framing the g25p summary as 24 prior generations synthesized, referencing Tables 01, 02, 04, and setting up the meta-analysis in Part IV.

**Correlates with:** Connects Chunk 3's validation tables (KRAS deviation, ECOG failure, OS pass) to the formal Virtual Trials Overview produced by g25p. The four sub-tables (01, 02, 04 — note Table 03 is not shown in this chunk; chunk preserves the source's numbering exactly) directly summarize content from Chunks 2 (Methods, P30 hazards), 3 (validation results), and prefigure Chunks 5–6 (meta-analysis and financial assessment that consumed the overview as input). The text repeatedly references S43–S56 supplementary outputs whose generating prompts are P37, P38, P39, P40, P41, P42 (all in Chunks 7–8). The grk4=o3pr r=1.0 finding here is the most striking inter-model finding and is mentioned again in Chunk 6 Discussion.

### chunk_05_part4_meta_analysis_part5_intro.md
**Source:** `main.tex` lines 1032–1294 (263 lines).
**Contents (in order):**
- **Meta-Analysis Comparisons: o3ph, ops4** — figure block of four images:
  - MAImage1 (Forest Plot of 2 Experimental Arms vs. Field, image `S58b.VIS.01.P44b-01.png`, "1) FOLFIRINOX 2) NAPOLI-1 3) Arm A")
  - MAImage2 (Toxicity vs. Survival Benefit, image `S58b.VIS.01.P44b-07.png`, "1) Arm D 2) MPACT 3) Arm A — Virtual Doublet less Toxic than Field")
  - MAImage3 (Radar Plot of 2 Arms vs. FOLFIRINOX, image `S58b.VIS.01.P44b-18.png`, "FOLFIRINOX best in OS Benefit; 100K Patient Triplet/Doublet in 3 Areas")
  - MAImage4 (FOLFIRINOX, NAPOLI-1, MPACT, Study Timeline, image `S58b.VIS.01.P44b-20.png`, "Precision Era: KRAS G12C Inhibitors")
- **Section: Part IV: Meta-Analysis**
  - *Subsection: 100K Triplicate, Virtual, In-Person Trials* — narrative: Arm D OS HR 0.76 (last), MPACT fourth, Arm A third (HR 0.69), NAPOLI-1 second (HR 0.67), FOLFIRINOX first (HR 0.57). Arm D least toxic with acceptable OS benefit. FOLFIRINOX OS Benefit 100, Patient Fitness ≈ equal vs. two Arms. Timeline: FOLFIRINOX 2011, MPACT 2013, NAPOLI-1 2014, 100K Virtual Trial 2025.
- **Large table: Meta-Analysis: Triplicate vs. Virtual vs. On-Site Trials** (label `MATables`, caption "Meta-Analysis Served as Input for Financial Assessment, o3ph. Ref: S58") containing three sub-tables:
  - **Table 1: Comparative Clinical and Methodological Metrics of In-Silico PDAC Trials** (11 rows × 5 columns: Metric, 100K Triplicate Control E, 100K Triplicate Triplet A, In-Silico Study 1 Digital Twin 2024, In-Silico Study 2 AI Simulation 2023). Rows include Patient Population Size (20,000 vs. 20,000 vs. ~861 vs. 30), Patient Profile (fitter >95% ECOG 0–1), Modeling Architecture (Exponential Weibull k=1.0 with 0.90 synergy for triplet vs. FarrSight digital twin vs. aiHumanoid DeepNEU v8.1 ~72k relationships), Median OS (6.1 mo / 8.7 mo / ~6.7-8.5 mo / N/R), OS HR (1.00 / ~0.69 / ~0.72 / N/R), Median PFS (3.1 / N/R / ~3.7-5.5 / N/R), Grade ≥3 AE (76.5% / 94.0% / N/R / N/R), Patient Archetypes (7 / 7 / N/R / N/R), Key Subgroup Finding (Arm A — enhanced benefit in ARCH-05 KRAS G12C subgroup), Source (Asghar et al. 2024; Danter et al. 2023 medRxiv preprint).
  - **Table 2: Comparative Clinical Metrics — Virtual Trial vs. Key Real-World PDAC Trials** (10 rows × 6 columns: Metric, Arm A, Arm D, MPACT, NAPOLI-1, PRODIGE 4). Median OS values: 8.7 / ~8.0 / 8.5 / 6.2 / 11.1 months. OS HRs: 0.69 / 0.76 / 0.72 / 0.67 / 0.57. Sources: Von Hoff et al. NEJM 2013; Wang-Gillam et al. Lancet 2016; Conroy et al. NEJM 2011.
  - **Table 3: Pooled Clinical Metrics and Head-to-Head Efficacy–Toxicity Scoring** (9 rows × 10 columns: Study ID, Study Type, Trial Arm/Regimen, N, Median OS mo, OS vs Control Δmo, Grade ≥3 AEs %, AEs vs Control Δ%, Source URL, Calculated ETS). Includes ETS (Efficacy-Toxicity Score) calculations: Arm A ETS −0.69 (negative), PRODIGE 4 FOLFIRINOX ETS +0.36 (slightly positive), MPACT ETS ~0.00 (baseline).
- **Financial Assessment and Value Proposition: o3ph, ops4** — figure block of four images:
  - FAImage1 (Total Project Cost Financial Estimates, image `S59b.VIS.01.P45b-11.png`, "Phase II/III Trials: Site/FTE Costs; $36K Triplicate")
  - FAImage2 (Time-to-Decision: 100K Triplicate vs. Field, image `S59b.VIS.01.P45b-13.png`, "One Month AI Turnaround Time")
  - FAImage3 (Risk-Time Matrix Estimates, Log Scale, image `S59b.VIS.01.P45b-18.png`, "100K Triplicate: Lowest $, Uncertainty")
  - FAImage4 (Ambitious AI Virtual Trial Forecasts, image `S59b.VIS.01.P45b-20.png`, "$19.96M Arm A Cost Savings")
- **Section: Part V: External Study Value Proposition**
  - *Subsection: Estimates vs. Single Virtual, QSP Trials* — concrete numbers: $36,000 triplicate, $120,000 single-run virtual, $600,000 QSP, $100M Phase III. Time-to-decision 1 month vs. 2.5–5 years. Recommends Arm D over Arm A based on toxicity benefits. Burn rate reduction $2.36M; cost reduction 99.9997% vs. Phase III per patient; ROI 55,000%.

**Correlates with:** Operationalizes the Virtual Trials Overview from Chunk 4. The three meta-analysis sub-tables consume S57 (overview from Chunk 4) and produce S58 (input to financial assessment in Chunk 6). Real-world trial comparators (MPACT, NAPOLI-1, PRODIGE 4) cited here are sourced from BibTeX entries in Chunks 9–10 — specifically the citations to Von Hoff, Wang-Gillam, and Conroy. The Asghar et al. and Danter et al. in-silico comparator studies were introduced in Chunk 1 Introduction. The four FAImage figures here are textually interpreted in Chunk 6 (Part V subsection "Estimates vs. Single Virtual, QSP Trials" begins here but its financial-assessment-table substantiation continues in Chunk 6). The Prompt 44 (meta-analysis) that produced these tables is in Chunk 8; Prompt 45 (financial) that produced these figures is also in Chunk 8.

### chunk_06_financial_table_discussion_limitations_conclusions.md
**Source:** `main.tex` lines 1295–1467 (173 lines).
**Contents (in order):**
- **Large table: Financial Assessment and Value Proposition** (label `FATables`, caption "Study Estimate vs. Leading Virtual and Clinical Trials, o3ph. Ref: S59") containing three sub-tables:
  - **Table 1: Financial & Methodological Comparison of In-Silico Trial Methodologies** (8 rows × 4 columns: Metric, 100K Patient Triplicate Simulation, Estimated Single-Run Virtual Trial (Standard), Estimated Advanced Mechanistic Model e.g. QSP). Key cells: **Total Project Cost — $36,330 actual vs. ~$120,000 estimated vs. ~$600,000+ estimated**. Researcher Labor Cost: ~$36,000 (1 × 4 weeks × $150/hr) vs. ~$115,000 (2 × 3 mo × $120/hr) vs. ~$576,000 (4 × 6 mo × $150/hr). AI/Cloud Compute: ~$330 vs. ~$3,000 vs. ~$50,000. Project Duration: 30 days vs. 3–6 months vs. 6–12 months. Cost per Virtual Patient: ~$0.36 vs. ~$120 vs. ~$1,000+. Cost of Reproducibility: ~$220 marginal for 2nd & 3rd runs.
  - **Table 2: Capital Efficiency and De-Risking — Virtual Triplicate vs. In-Person PDAC Trials** (6 rows × 4 columns: Financial Metric, 100K Triplicate, Phase II PDAC Trial, Phase III PDAC Trial). Total Budget: ~$36,330 vs. ~$15–25 million vs. ~$80–150 million. Duration: ~30 days vs. ~2–3 years vs. ~4–6 years. Cost per Patient: ~$0.36 vs. ~$133,000 (e.g., $20M/150 patients) vs. ~$125,000 (e.g., $100M/800 patients). Capital at Risk: ~$36K vs. full $20M+ vs. full $100M+.
  - **Table 3: Grant Funding Justification Framework** (4 rows × 4 columns: Value Driver & Justification, Key Supporting Finding from Simulation, Quantifiable Financial Impact / Startup Value, Source of Finding). Drivers: Optimizing Clinical Trial Design (KRAS G12C subgroup driver, ARCH-05); Justifying the Triplicate Methodology (high cross-trial consistency, Arm A vs. E HR variance < 0.01, marginal cost $220 for runs 2 & 3); Accelerating Time-to-Market (30 days vs. 3–5 years, NPV impact ~25–50% gain from 3-year acceleration, $500M in 10 years vs. 8 years yields ~$40M more NPV); Informing Future R&D (ECOG profile mismatch identified for platform enhancement).
- **Section: Discussion**
  - *Subsection: Triplicate Trials* — discusses pushing limits of ChatGPT Deep research, citing prior Kawchak studies (glioblastoma, lung adenocarcinoma). Notes how Prompt 30 used Kaplan-Meier censoring at 24 months while raw event times were independent exponential draws. Notes consistency across internal/external validations despite the KRAS-mutant naming issue and ECOG healthier-patient preference.
  - *Subsection: Multiple Verifications* — recaps the 8.65 reproducibility score, the g25p archetype mPFS row-consistency advantage, the grk4=o3pr r=1.0 correlation, the high meta-verification radar (MVImage3) and ridge (MVImage4) plot scores (8.8–10.0 across 10 metrics), the three model-pair exact agreements (<0.1), and the largest deviations of Table 3 (grk3) and Table 2-R1 (ops4) over 0.60 magnitude.
  - *Subsection: Overview, Meta-Analysis, Financial* — reviews the Virtual Trials Overview "Exceptional Reproducibility", "Strong Inter-Model Agreement", "Highly Robust" findings; reiterates patient population per arm (20,000) vs. largest in-person trial (861); Arm D missing PFS values due to less focus; OS forest plot favored FOLFIRINOX and NAPOLI-1 over Arm A; Arm D toxicity advantages; financial advantages including NPV impact "Realizing a given cash flow 3 years earlier can increase its present value by ~25–50% (at a 15% discount rate). For instance, $500M in 10 years vs 8 years yields ~$40M more NPV." The $19.96M cost saving for avoiding Arm A; $2.36M burn rate reduction; 99.9997% cost reduction; 55,000% ROI.
- **Section: Limitations and Future Work** — patient detail reproducibility limit (prior 10K-patient monthly updates had large fluctuations, so 100K single-line entries used here); chart color issues with ChatGPT log file Part I; ops4 chart formatting issues; external validation only via Flatiron Health abstract extrapolated by AI; only o3ph, o3pr, o3ch could process the 5 MB log CSV files (g25p hit 4,940,792 token log file exceeding its 1M context); g25p's 24-file Virtual Trials Overview produced 6,544-token output from 147,531-token input (<5% ratio, explaining why Arm D PFS info was less prominent); larger follow-up prompts in same conversation often yielded poorer outputs.
- **Section: Conclusions** — reasserts the 7 archetypes from doi.org/10.5281/zenodo.15735067, Phase III equivalence via randomization and parallelization across five 20,000-patient cohorts, Arm A best by Prompt 30 parameters but Arm D standing out for lower toxicity. KRAS notation issue (KRAS_G12C vs. KRAS-mutant) caused ~90–91% deviation consistently across trials. Five-model cross-verifications worked but only o3ph generated a report + log of patient data in ~20–30 minutes. g25p's 24-output overview was a remarkable feat. Final framing: "conversational AI models are no longer confined to only probabilistic next token predictions, but rather effective data-driven engines at scale" with citations to prior Kawchak PDAC, glioblastoma, and lung studies.

**Correlates with:** Closes the loop on Chunks 1–5. The three financial sub-tables consume the meta-analysis from Chunk 5 (S58) and the Virtual Trials Overview from Chunk 4 (S57); they are produced by Prompt 45 (Chunk 8). Discussion subsections reference figures from every prior chunk: CVImage3/4 (Chunk 3 figures), MVImage3/4 (Chunk 4 figures), MAImage1–4 (Chunk 5 figures), FAImage1–4 (Chunk 5 figures), TriplicateAnalysisTable (Chunk 3 table), VTOverviewTables (Chunk 4 table), MATables (Chunk 5 table), FATables (this chunk's table). Limitations cite the 408,081-word dataset and 1M-token limits originally mentioned in Chunk 1 Introduction.

### chunk_07_data_availability_prompts_part1.md
**Source:** `main.tex` lines 1468–2540 (1,073 lines).
**Contents (in order):**
- **Section: Data availability** — two-column itemized list of all supplementary files in the Zenodo deposit (citing `19KawchakSimPDAC`):
  - Virtual Trial 1: S33.TRL.13.P30 report + summary, S33.TRL.13.P30.LOG.CSV log file, S35.VER.02.P32 internal validation, S35b.VER.03.P34 external validation, S36.VIS.01.P33 + IMAGES.
  - Virtual Trial 2: S37, S37.LOG.CSV, S38.VER.01.P32, S38b.VER.02.P35, S39.VIS.01.P33 + IMAGES.
  - Virtual Trial 3: S40, S40.LOG.CSV, S41.VER.01.P32, S41b.VER.02.P36, S42.VIS.01.P33 + IMAGES.
  - Cross-Verifications: S43.DAT.02.TAB dataset, S43.TST.01.P37 (grk4), S44.TST.02.P37 (grk3), S45.TST.03.P37 (ops4), S46.TST.04.P37 (g25p), S47.TST.05.P37 (o3pr), S48.VIS.01.P38 + IMAGES + CODE, S49.VIS.02.P39 + IMAGES + CODE.
  - Meta-Verifications: S44.DAT.03.TAB dataset, S50.TST.01.P40 (grk4), S51 (grk3), S52 (ops4), S53 (g25p), S54 (o3pr), S55.VIS.01.P41 + IMAGES + CODE, S56.VIS.02.P42 + IMAGES + CODE.
  - Virtual Study Overview: S57.REP.01.P43 (g25p), S57b.VIS.01.P43b + IMAGES + CODE1 + CODE2.
  - Meta-Analysis: S58.REP.02.P44 (o3ph), S58b.VIS.01.P44b + IMAGES + CODE1 + CODE2.
  - Financial Assessment: S59.REP.03.P45 (o3ph), S59b.VIS.01.P45b + IMAGES + CODE1 + CODE2.
- **Table: In Silico Trial: Prompt 30 (I/II)** (label `PromptTrialI`, caption "Ref: S33.TRL.13.P30, S37.TRL.14.P30, S40.TRL.15.P30") — the master simulation prompt. Sections: SYSTEM ROLE (Clinical-Trial-Simulation Engine for one virtual phase-III trial in advanced PDAC), Global Configuration (Seed 20250624; Arms A=D+M+I, B=M+I, C=D+I, D=D+M, E=nal-IRI+5FU; N=20,000/arm = 100,000 total; censor at 24 months; Weibull k_PFS = k_OS = 1.0), Patient Generation & Randomization (3-step process: master cohort by archetype prevalence → stratified randomization → baseline characteristics with Gaussian copula), the **Archetype Prevalence Table** (ARCH-01 through ARCH-07 with prevalences 0.20/0.20/0.10/0.05/0.05/0.10/0.30, ages, stage LAPC/Mets ratios, ECOG distributions, key genomics, CA19-9 μ, σ values), Efficacy Model (baseline hazards λ_PFS=ln(2)/3.1, λ_OS=ln(2)/6.1; Component HRs Daraxonrasib OS=0.85 PFS=0.80, Mitazalimab OS=0.90 PFS=0.95; Arm HR = ΠHR × synergy_factor where 0.90 for triplet only; Example Arm A OS HR = 0.85×0.90×0.90 = 0.6885), Safety Model (per-arm monthly G3+ AE probabilities 0.12/0.09/0.08/0.07/0.06 for A/B/C/D/E), Biomarker Adjustments (ARCH-05 KRAS G12C only benefits from Daraxonrasib; no other tumor-biology effects).
- **Table: In Silico Trial: Prompt 30 (II/II)** (label `PromptTrialII`, same Ref): Event Time Generation (three independent exponential draws per patient, no competing risks, no PFS-from-progression derivation), Mandatory File Output (`pdac_trial_events.csv` with exactly 11 columns: patient_id, arm, archetype, age, stage_iv, ecog, kras_g12c, gbrca, ca19_9, time_to_progression_or_death, time_to_death, time_to_first_G3_AE; patient_id 000001–100000; 2 decimal places for non-integers; sorted by patient_id ascending). Report Generation (ICH E3-compliant single plain-text document with exact headings): Title Page, Synopsis, Study Objectives, Simulation Methodology (C1 design, C2 statistical models & software, C3 randomisation & seed control), Patient Population Characteristics → Table 5-1 (R1=Arm A through R5=Arm E; C1=Age mean, C2=Stage IV %, C3-C5=ECOG 0/1/2 %, C6=KRAS-mutant %, C7=gBRCA-mutant %, C8=CA19-9 mean), Efficacy Outcomes → Table 6-1 (C1=Median PFS mo, C2=Median OS mo, C3=12-month OS rate %, C4=PFS HR vs Control, C5=OS HR vs Control; KM analysis censored at 24 mo), Safety Outcomes → Table 7-1 (C1 = Any ≥G3 AE %, derived as % of patients where time_to_first_G3_AE ≤ 24 months), Archetype Sub-Analyses → Tables 8-1 (Median PFS by Archetype and Arm) and 8-2 (Median OS by Archetype and Arm), Statistical Analysis, Discussion and Conclusions. Plus a Download Link instruction.
- **Table: Internal Validation: Prompt 32** (label `PromptIV`, caption "Ref: S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32") — six head-to-head comparison tables between summary report tables and the attached log file CSV: Table 1 Overall Cohort Distribution Verification (6R x 4C: Arm A-E + Total × C1 Arm, C2 CSR Patient Count, C3 Log Patient Count, C4 Discrepancy + 3 sample calculations); Table 2 Baseline Characteristics Correlation Check (Focus on Arm A) (5R: Mean Age, Stage IV, ECOG 1, KRAS-mutant, gBRCA-mutant); Tables 3, 4, 5, 6 (Median OS, Median PFS, 12-Month OS Rate, Grade ≥3 AE Incidence) each 5R × 4C; each table requires +3 verifiable sample calculations referencing patient IDs and table sources.
- **Table: External Validation: Prompt 34/35/36** (label `PromptEV`, caption "Ref: S35b.VER.03.P34, S38b.VER.02.P35, S41b.VER.02.P36") — external validation prompt that uses the **Flatiron Health metastatic pancreatic adenocarcinoma with liposomal irinotecan abstract** (introduced by Prompt 34 then extrapolated by o3ch into trial-specific Prompts 35 and 36, in turn run against each patient log file). Defines T2 OS validation (Mean OS % at months 3–24 with ±5% threshold; SD of monthly absolute differences; Pearson r against Flatiron OS%) and T3 ECOG Validation.
- **Table: Trial Charts: Prompt 33** (label `PromptTrialCharts`, caption "Ref: S36.VIS.01.P33, S39.VIS.01.P33, S42.VIS.01.P33") — prompt for generating chart visualizations from log files (yielding the Violin Plot, Grade ≥3 AE Incidence by Arm, KM PFS Curves, OS by ECOG, etc. seen in Chunk 2).
- **Table: Trial vs. Trial: Prompt 37 (I/II)** (label `PromptTVTI`) — cross-trial verification prompt for the five AI models (grk4, grk3, ops4, g25p, o3pr) operating on the trial reports.
- **Table: Trial vs. Trial: Prompt 37 (II/II)** (label `PromptTVTII`) — continuation of P37.
- **Table: (P38 charts prompt)** (label `PromptMVMCharts`, caption "Ref: S48.VIS.01.P38") — Python/ops4 visualization prompt for cross-model results.
- **Table: Trial vs. Trial Charts: Prompt 39** (label `PromptTVTCharts`, caption "Ref: S49.VIS.02.P39") — Python/ops4 visualization prompt for cross-trial results.
- **Table: Log vs. Report: Prompt 40 (I/II)** (label `PromptLRI`) — meta-verification prompt comparing each AI model's report-to-log analysis across the three trials.
- **Table: Log vs. Report: Prompt 40 (II/II)** (label `PromptLRI` — note duplicate label preserved verbatim from source) — continuation of P40.

**Correlates with:** This chunk is the **prompt provenance** for all values appearing in Chunks 2–6. Every clinical, methodological, financial, and validation outcome traces back to one of these prompts:
- Patient log table in Chunk 2 → Prompt 30 II/II's file output spec.
- Trial 1/2/3 Table 5-1 baseline characteristics in Chunk 3 → Prompt 30 I/II's archetype prevalence table + Prompt 30 II/II's Report Structure Table 5-1 spec.
- Trial 1/2/3 Table 2 internal validation in Chunk 3 → Prompt 32.
- Trial 1/2/3 Table T2 & T3 external validation in Chunk 3 → Prompt 34/35/36 against Flatiron Health.
- CVImage1–4 in Chunks 3/4 → Prompt 38, 39 (visualization) + Prompt 37 cross-verification data.
- MVImage1–4 in Chunk 4 → Prompt 40 meta-verification data + Prompts in Chunk 8 (P41, P42 visualizations).
- The reproducibility score 8.65 and the grk4=o3pr r=1.0 correlation → outputs S43–S47 produced by Prompt 37.

### chunk_08_prompts_part2_acknowledgments.md
**Source:** `main.tex` lines 2541–3621 (1,081 lines).
**Contents (in order):**
- **Table: Log vs. Report vs. Model Charts: Prompt 41** (label `PromptLRMC`, caption "Ref: S55.VIS.01.P41") — visualization prompt for cross-model meta-verification analysis using outputs S50–S54.
- **Table: Log vs. Report vs. Trial Charts: Prompt 42** (label `PromptLRTC`, caption "Ref: S56.VIS.02.P42") — visualization prompt for cross-trial meta-verification analysis.
- **Table: In Silico Trial Overview: Prompt 43** (label `PromptISTO`, caption "Ref: S57.REP.01.P43") — the prompt that g25p used to synthesize 24 prior generations into the Virtual Trials Overview tables (Table 01, 02, 03, 04 — Chunk 4 displays 01, 02, 04; 03 is referenced as Source: Synthesized from trial reports). This is the prompt that exploited g25p's 1M-token context capability.
- **Table: Trial Overview Charts: Prompt 43b1** (label `PromptTROC1`, caption "Ref: S57b.VIS.01.P43b") — first ops4 chart prompt for the Virtual Trials Overview.
- **Table: Trial Overview Charts: Prompt 43b2** (label `PromptTROC2`, same Ref) — second ops4 chart prompt.
- **Table: Meta-Analysis: Prompt 44 (I/III)** (label `PromptMAI`, caption "Ref: S58.REP.02.P44") — meta-analysis prompt for o3ph Deep research that consumed S57 + online clinical trial data, yielding the 9,574-word output containing the three meta-analysis sub-tables in Chunk 5.
- **Table: Meta-Analysis: Prompt 44 (II/III)** (label `PromptMAII`) — continuation, defining the comparators MPACT, NAPOLI-1, PRODIGE 4 and the in-silico comparators.
- **Table: Meta-Analysis: Prompt 44 (III/III)** (label `PromptMAIII`) — continuation, scoring formulas (Calculated ETS) and head-to-head methodology.
- **Table: Meta-Analysis Charts: Prompt 44b** (label `PromptMACharts`, caption "Ref: S58b.VIS.01.P44b") — ops4 visualization prompt producing MAImage1–4 (Forest plot, Toxicity vs. Survival, Radar, Timeline) in Chunk 5.
- **Table: Financial Assessment: Prompt 45 (I/IV)** (label `PromptFAI`, caption "Ref: S59.REP.03.P45") — the o3ph financial assessment prompt consuming S57 + S58 and producing the three financial sub-tables in Chunk 6. Specifies labor cost ($150/hr × 60 hrs/wk × 4 weeks), cloud compute estimates, comparisons to Phase II ($15–25M) and Phase III ($80–150M).
- **Table: Financial Assessment: Prompt 45 (II/IV)** (label `PromptFAII`) — continuation, defining the grant funding justification framework and value drivers.
- **Table: Financial Assessment: Prompt 45 (III/IV)** (label `PromptFAIII`) — continuation, NPV impact methodology, cost-of-reproducibility ($220 marginal), ROI calculations.
- **Table: Financial Assessment: Prompt 45 (IV/IV)** (label `PromptFAIV`) — continuation, completing the assessment framework.
- **Table: Financial Assessment Charts: Prompt 45b** (label `StandardQ`, caption "Ref: S59b.VIS.01.P45b") — ops4 visualization prompt producing FAImage1–4 (Total Project Cost, Time-to-Decision, Risk-Time Matrix, Ambitious AI Virtual Trial Forecasts) in Chunk 5.
- LaTeX `\bibliographystyle{unsrturl}` + `\bibliography{references}` directives at line 3581–3582 — these consume the BibTeX entries in Chunks 9–10.
- **Section: Acknowledgments** — author acknowledges OpenAI (ChatGPT), Google (Gemini), Anthropic (Claude), and xAI (Grok) for access.
- **Section: Ethical disclosures** — "The author of the article declares no competing interests."
- **Section: Rights and permissions** — CC BY 4.0 with link to creativecommons.org/licenses/by/4.0/.
- **Section: About this study** — "Kawchak K. ChatGPT 100,000 Patient 24-Month In Silico Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate. Zenodo. 2025; 10.5281/zenodo.16415815" citing entry `19KawchakSimPDAC`.
- `\end{document}` closing.

**Correlates with:** This chunk is the **prompt provenance** for everything visible in Chunks 4–6 that is not covered by Chunk 7's prompts:
- VTOverviewTables in Chunk 4 → Prompt 43 (g25p).
- MAImage1–4 figures in Chunk 5 → Prompt 44b (ops4 charts) running on Prompt 44 output.
- MATables (Tables 1, 2, 3 of meta-analysis) in Chunk 5 → Prompt 44 (I/III, II/III, III/III) by o3ph Deep research.
- FAImage1–4 figures in Chunk 5 → Prompt 45b (ops4 charts) running on Prompt 45 output.
- FATables (Tables 1, 2, 3 of financial assessment) in Chunk 6 → Prompt 45 (I/IV through IV/IV) by o3ph.
- MVImage1–4 figures in Chunk 4 → Prompts 41 and 42 (ops4 charts) running on Prompt 40 meta-verification outputs (P40 itself in Chunk 7).

The Acknowledgments section names the four AI vendors whose models are the subject of every cross-verification finding in Chunks 3–6. The Rights and permissions (CC BY 4.0) governs reuse.

### chunk_09_bibtex_entries_part1.md
**Source:** `references.bib` lines 1–304 (304 lines, **75 BibTeX entries**).
**Contents:** Entries 1–75 in source order. The categories of entries in this chunk include:
- **AI tool/platform citations:** Claude (and 3.5, 3.5 New, 3.7, 3.7-2, 4, Sonnet4, Opus4), ChatGPT (and o1, o3-mini, o3, o3-card, o3-pro, o3-pro-2, 4o, GPT-4.5, GPT-4.5 Card), Grok (3 and 4), Gemini (2.5 Pro, 2.5 Pro Preview, AI Studio), Meta AI. Used for the AI Models list in Chunk 2.
- **Tools:** Google Colab, Visual Studio Code, Google Docs, Google Scholar, LangChain, AutoGen, CrewAI. Used as supporting infrastructure citations.
- **Author's prior works (Kawchak):** `KawchakAgents` (YouTube), `01Kawchak_Kevin_10Jul24` (Large Language Models for Early Phase GenAI Drug Discovery), and additional Kawchak Zenodo deposits including the GitHub `GitHub29May25` (Quad-LLM) and `GitHub24Jun25` (Digital_Twin_PDAC), each linked to DOI 10.5281/zenodo.13273141 family.
- **Key citations cited in the paper body (Chunk 1 Introduction):**
  - `18KawchakPDAC` — Kawchak's prior PDAC digital twin proposal (Proposal A, doi.org/10.5281/zenodo.15735068).
  - `17KawchakGlioblastoma` — Glioblastoma trial article.
  - `16KawchakLung` — Lung adenocarcinoma trial article.
  - `10Kawchak_mAbInContext_2024`, `09Kawchak_mAbBioprocess_2024`, `08kawchak2024Paclitaxel` — earlier Kawchak studies.
  - `19KawchakSimPDAC` — Zenodo deposit of the current study (doi.org/10.5281/zenodo.16415815).
  - **Introduction literature citations:** `03IntroArcus`, `02IntroArcus` (Arcus Biosciences PRISM-1, ARC-8), `04IntroOsipov` (Nature Cancer 2024 Molecular Twin), `10IntroAsghar` (Asghar et al. 2024 digital twin), `01IntroSayama` (Toshimoto et al. 2024 IO-QSP), `07IntroSarno` (2025 Phase III AVATAR Trial), `06IntroKo` (Ko et al. April 2025 MORPHEUS hybrid control), `09IntroPourmousa` (Pourmousa et al. April 2025 UNC/MIT screening).
  - **External validation source:** `01METFlatiron` — the Flatiron Health metastatic pancreatic cancer with liposomal irinotecan abstract used by Prompts 34/35/36 (Chunk 7).
- **Other:** WSJ News Andrew Ng commentary, IBM "What Are Large Language Models", artificialanalysis.ai comparison, Sequoia Capital AI agentic workflows.

### chunk_10_bibtex_entries_part2.md
**Source:** `references.bib` lines 305–548 (244 lines, **76 BibTeX entries**, including 3 trailing "Quotes" lines preserved verbatim from the source).
**Contents:** Entries 76–151 in source order. Mostly arXiv/preprint and journal entries covering:
- **LLM-in-chemistry/biology surveys and methods:** Ramos/Collison/White 2024 (Review of LLMs and Autonomous Agents in Chemistry), Guo et al. 2024 (Molecule Puzzles multimodal benchmark), Tan 2024 (Transformer chemical language model), Chacko et al. 2024 (Spectro IR/NMR multi-modal molecule elucidation), Weggen et al. 2023 (ADC conjugation kinetics), Bauer et al. 2024 (Procollagen-lysine 2-oxoglutarate 5-dioxygenases for therapeutic T-cell bispecific mAbs in CHO cells), Reis-Claro et al. 2024 (iPLUS biopharmaceuticals).
- **Biopharmaceutical and bioprocess AI:** Parthiban et al. 2023 (plant-derived biopharmaceuticals), Smiatek et al. 2021 (recurrent neural networks for biopharmaceutical processes), Wainaina/Taherzadeh 2023 (automation and AI in filamentous fungi bioprocesses), Vinestock et al. 2024 (precision fermentation).
- **General LLM citations:** Pal et al. 2023 (ChatGPT in drug discovery, IJS), Chen et al. 2024 (LLM Multi-Agent Framework for Protein Engineering), Liu & Wang 2024 (GenoTEX benchmark), M. Bran et al. 2024 (Augmenting LLMs with chemistry tools, Nature Machine Intelligence), Li et al. 2024 (BiomedRAG), Chen et al. 2024 (Chemist-X).
- **Trailing lines:** the literal text "Quotes\nQuotes\nQuotes\n" at lines 545–547 of references.bib (preserved verbatim as found in source).

**Correlates with chunk_09:** Together, chunks 9 and 10 supply every `\cite{...}` key used in chunks 1–8 (e.g., `\cite{18KawchakPDAC}`, `\cite{01METFlatiron}`, `\cite{ChatGPTo3}`, `\cite{Gemini25Pro}`, `\cite{Opus4}`, `\cite{Grok4}`, etc.). The bibliography is intentionally split roughly in half by entry count (75 + 76 = 151 entries total). Entries cited inline in Chunks 1, 2, 5, 6 are predominantly resolved from Chunk 9; Chunk 10 contains many entries that establish the broader LLM-for-science literature context that informs the author's methodology even when not directly cited in the body.

---

## Cross-Chunk Correlation Map

Below is a high-level dependency / reference graph among the chunks. The "produced by" direction is from prompt-bearing chunks (7–8) into result-bearing chunks (2–6).

```
Chunk 1 (Title/Abstract/Intro)
   │  introduces 6 AI models, archetypes, drug combo, prior literature
   ▼
Chunk 2 (Methods + Patient Log Table + Part I section)
   │  defines workflow + cites S33/S37/S40 logs   ◄── produced by Prompt 30 (Chunk 7)
   ▼
Chunk 3 (Internal/External Validations Tables: 5-1, 2, T2, T3)
   │  Table 5-1 baselines           ◄── Prompt 30 Report Structure (Chunk 7)
   │  Table 2 internal validation   ◄── Prompt 32 (Chunk 7)
   │  Table T2/T3 external valid.   ◄── Prompts 34/35/36 (Chunk 7)
   ▼
Chunk 4 (Part II Cross-Verifications + Virtual Trials Overview)
   │  CVImage1–4 + MVImage1–4       ◄── Prompts 37, 38, 39, 40 (Chunks 7–8 boundary)
   │                                ◄── Prompts 41, 42 visualizations (Chunk 8)
   │  Virtual Trials Overview       ◄── Prompt 43 by g25p (Chunk 8)
   ▼
Chunk 5 (Part IV Meta-Analysis + Part V Financial intro)
   │  MAImage1–4                    ◄── Prompt 44b visualizations (Chunk 8)
   │  MATables (Tables 1, 2, 3)     ◄── Prompt 44 I/II/III by o3ph (Chunk 8)
   │  FAImage1–4 (placed here)      ◄── Prompt 45b visualizations (Chunk 8)
   ▼
Chunk 6 (FATables + Discussion + Limitations + Conclusions)
   │  FATables (Tables 1, 2, 3)     ◄── Prompt 45 I–IV by o3ph (Chunk 8)
   │  Discussion synthesizes all prior chunks
   ▼
Chunks 7 + 8 (Data availability + Prompts P30–P45b + Acknowledgments etc.)
   │  Contains every prompt used to produce the results in Chunks 2–6.
   ▼
Chunks 9 + 10 (BibTeX entries 1–151)
   │  Resolve every \cite{...} key used in Chunks 1–8.
   │  Critical keys:
   │    • 18KawchakPDAC, 17KawchakGlioblastoma, 16KawchakLung (prior Kawchak work)
   │    • 19KawchakSimPDAC (this study's Zenodo deposit)
   │    • 01METFlatiron (external validation data source)
   │    • 01IntroSayama through 10IntroAsghar (Intro literature review)
   │    • ChatGPTo3, ChatGPTo3pro, Gemini25Pro, Grok4, Grok3, Opus4, Sonnet4,
   │      OpenAI_GPT-4o, Google_AI_Studio, ChatGPTo3Card (AI tool citations)
```

### Recurring Threads to Track Across Chunks

When reading or rewriting this paper for a new physical AI oncology trial, the following threads tie the chunks together and should be preserved or adapted as a unit. Each item lists the chunks where it appears.

1. **The KRAS-mutant labeling discrepancy** (Chunks 1, 3, 4, 6) — report says "KRAS-mutant (>90%) in pancreatic cancer", log says "KRAS_G12C (1–2% of KRAS-mutants)", yielding ~86% absolute deviation **with remarkable cross-trial consistency** (10.0/10 cross-model consistency score for the deviation itself). This is the paradigmatic example of how a labeling error can be perfectly reproducible.

2. **The Arm A → Arm D recommendation pivot** (Chunks 1, 5, 6) — Arm A (triplet) has best efficacy in the simulation but is dominated in real-world trial comparisons by FOLFIRINOX and NAPOLI-1. Arm D (Daraxonrasib + Mitazalimab doublet) emerges with lower toxicity, comparable efficacy, and superior clinical feasibility, leading to a recommendation to skip Arm A in any future in-person trial — yielding a projected $19.96M cost saving.

3. **The five-AI-model cross-verification framework** (Chunks 2, 3, 4, 6) — grk4, grk3, ops4, g25p, o3pr each given the same prompt template across three trial reports. Reproducibility score 8.65/10. grk4 = o3pr at r=1.0; three exact (<0.01) agreements grk4–g25p, grk4–o3pr, g25p–o3pr.

4. **The 1M-token context advantage of g25p** (Chunks 1, 2, 4, 6) — g25p was the only available model capable of synthesizing 24 separate generations into the Virtual Trials Overview (S57) because other models' context windows were too small. However, g25p could not process the 4.94M-token log CSVs (S33.LOG.csv etc.) which were handled by o3ph/o3pr/o3ch instead.

5. **The 99.9997% cost reduction story** (Chunks 1, 5, 6) — $36,330 actual vs. $100M Phase III, with corollary $0.36 per virtual patient cost.

6. **The seven patient archetypes** (Chunks 2, 5, 7) — ARCH-01 Young_Fit_Metastatic through ARCH-07 Advanced_Refractory_PS1 with prevalences 20/20/10/5/5/10/30%. ARCH-05 (Metastatic_KRAS_G12C) is the only archetype with conditional efficacy logic — its benefit is contingent on Daraxonrasib being present in the arm.

7. **The Prompt 30 multiplicative hazard model** (Chunks 2, 7) — baseline λ_PFS = ln(2)/3.1, λ_OS = ln(2)/6.1, Daraxonrasib OS HR 0.85 PFS HR 0.80, Mitazalimab OS HR 0.90 PFS HR 0.95, 0.90 synergy factor for triplet. Worked Example: Arm A OS HR = 0.85 × 0.90 × 0.90 = 0.6885.

8. **Three real-world Phase III comparators** (Chunks 1, 5, 6, 8) — MPACT (Von Hoff et al. NEJM 2013, OS 8.5 mo HR 0.72), NAPOLI-1 (Wang-Gillam et al. Lancet 2016, OS 6.2 mo HR 0.67), PRODIGE 4 / ACCORD11 (Conroy et al. NEJM 2011, OS 11.1 mo HR 0.57).

9. **External validation methodology** (Chunks 2, 3, 7) — Flatiron Health metastatic pancreatic adenocarcinoma with liposomal irinotecan abstract (Prompt 34) extrapolated by o3ch into trial-specific Prompts 35/36. OS validation pass (Pearson r 0.999); ECOG validation fail (~5/14/19% absolute differences).

10. **The S## supplementary file numbering scheme** — every S## reference in Chunks 2–6 captions corresponds to a downloadable supplementary file listed in Chunk 7's Data availability section, generated by a prompt in Chunks 7 or 8, and visualized by a Python script (also referenced by S## codes ending in `_CODE` or `.IMAGES`).

---

## Notes for the Downstream Reader (Claude Code Opus 4.7 1M Max)

This corpus is structured to support authoring a **new physical AI oncology trial paper** that may parallel, contrast, or extend this study's methodology. When drawing on these chunks:

- **Methodological reuse:** Prompt 30 (Chunk 7) is the most reusable artifact — it can be adapted to other cancer types by swapping the archetype prevalence table, the drug component HR table, the safety hazard table, and the report structure. The five-AI cross-verification framework (Prompt 37, Chunk 7) and the meta-verification framework (Prompt 40, Chunk 7) are similarly portable.

- **Quantitative reuse:** Specific values from Chunk 3 (validation deviations), Chunk 4 (consistency scores), Chunk 5 (real-world Phase III comparator data), and Chunk 6 (financial estimates) can be cited or contrasted against in a new paper. Always trace numbers back to their generating prompt (Chunks 7–8) and the S## supplementary file to confirm provenance.

- **The author has published several adjacent studies** — see `\cite{17KawchakGlioblastoma}`, `\cite{16KawchakLung}`, `\cite{18KawchakPDAC}` in Chunks 9–10. A new physical AI oncology trial paper in this line should likely cite all four.

- **The author's framing of conversational AI** as "no longer confined to only probabilistic next token predictions, but rather effective data-driven engines at scale" (Chunk 6 Conclusions) is the philosophical thesis worth preserving or arguing against.

- **Verbatim integrity:** The body content in chunks 1–8 is raw LaTeX from `main.tex`. To render it as Markdown for human reading, one would need to strip `\textbf{...}` → `**...**`, `\textit{...}` → `*...*`, `\section{X}` → `# X`, `\subsection{X}` → `## X`, tabular environments → Markdown tables, etc. The choice to retain LaTeX preserves every nuance (line breaks, spacing, escape sequences) that a downstream consumer might need to reproduce or re-render the paper. The same applies to BibTeX in chunks 9–10.

- **Image references** (`\includegraphics{images/...}`) remain inline. The actual image files are not part of this chunked corpus.

---

## File Manifest

| File | Source Lines | Lines in Chunk | @Entries | Sections / Major Tables |
| ---- | ------------ | -------------- | -------- | ----------------------- |
| chunk_01_title_abstract_introduction.md | main.tex 1–214 | 214 | — | Preamble, Title, Author, Abstract (6 labeled paragraphs), ToC, Pipeline Figure, Introduction with 2 subsections |
| chunk_02_methods_part1_patient_log_analysis.md | main.tex 215–465 | 251 | — | Methods (2 subsections + AI Models list of 11), Part I section, Patient Log Analysis Table (3 sub-tables), Patient Log Analysis subsection, Figures 2–5 |
| chunk_03_part1_internal_external_validations.md | main.tex 466–779 | 314 | — | Internal & External Validations subsection, Trial Analysis & External Validations Table (9 sub-tables: 3 × T5-1, 3 × Table 2, 3 × T2, 3 × T3), Multi-Model Cross-Verifications figures CVImage1–4 |
| chunk_04_part2_cross_verifications_part3_overview.md | main.tex 780–1031 | 252 | — | Part II section with 2 subsections, Multi-Model Meta-Verifications figures MVImage1–4, Virtual Trials Overview Table (Tables 01, 02, 04), Part III section |
| chunk_05_part4_meta_analysis_part5_intro.md | main.tex 1032–1294 | 263 | — | Meta-Analysis figures MAImage1–4, Part IV section, Meta-Analysis Tables 1/2/3, Financial Assessment figures FAImage1–4, Part V section text |
| chunk_06_financial_table_discussion_limitations_conclusions.md | main.tex 1295–1467 | 173 | — | Financial Assessment Tables 1/2/3, Discussion section (3 subsections), Limitations and Future Work section, Conclusions section |
| chunk_07_data_availability_prompts_part1.md | main.tex 1468–2540 | 1073 | — | Data availability list, Prompts P30 I/II + II/II, P32, P34/35/36, P33, P37 I/II + II/II, P38, P39, P40 I/II + II/II |
| chunk_08_prompts_part2_acknowledgments.md | main.tex 2541–3621 | 1081 | — | Prompts P41, P42, P43, P43b1, P43b2, P44 I/II/III, P44b, P45 I/II/III/IV, P45b, Acknowledgments, Ethical disclosures, Rights and permissions, About this study |
| chunk_09_bibtex_entries_part1.md | references.bib 1–304 | 304 | 75 | BibTeX entries 1–75: AI tool citations, Kawchak's prior works, Introduction literature, Flatiron source |
| chunk_10_bibtex_entries_part2.md | references.bib 305–548 | 244 | 76 | BibTeX entries 76–151: LLM-in-chemistry/biology, biopharmaceutical AI, general LLM citations + 3 trailing literal "Quotes" lines from source |

**Total:** 4,169 lines across 10 files. Concatenating chunks 1–8 reproduces `main.tex` lines 1–3621 byte-for-byte (the final 3 trailing blank lines of `main.tex` after `\end{document}` are not included). Concatenating chunks 9–10 reproduces `references.bib` byte-for-byte (all 548 lines).
